Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions

This document aims to provide interim guidance on the risks for fully vaccinated individuals to develop or transmit infection that will give rise to severe COVID-19 disease in the context of the current epidemiological and vaccine coverage situation in the EU/EEA.

The document assesses the following questions: 1.What is the risk of developing severe COVID-19 for a fully vaccinated individual? 2.What is the risk of severe COVID-19 for an unvaccinated individual in contact with a fully vaccinated person

who has recently been exposed to SARS-CoV-2 infection?